Metastatic Prostate Cancer Patients Show No Survival Benefit with Custirsen

Metastatic Prostate Cancer Patients Show No Survival Benefit with Custirsen
Patients with previously treated metastatic, castration-resistant prostate cancer (mCRPC) see no benefit when custirsen is added to the combination of Jevtana (cabazitaxel) and prednisole, according to the results of a Phase 3 clinical trial. The data, presented at the recent European Society for Medical Oncology (ESMO) 2016 Congress, show that patients treated with the custirsen,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *